ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2022
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.Frontiers in immunology · 2024Pooled it
- Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT.Health technology assessment (Winchester, England) · 2024Trial
- Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5-Year Real-Life Experience With Dupilumab.International journal of dermatology · 2026Article
- Atopic Dermatitis in Children: Differential Diagnosis and Mimickers.Children (Basel, Switzerland) · 2026Review
- Review
- A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia.Postepy dermatologii i alergologii · 2026Article
- Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies.Antibodies (Basel, Switzerland) · 2025Review
- Clinical Outcomes of Dupilumab-Associated Ocular Surface Disease in the Paediatric Population.Cureus · 2025Article
- Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review.Clinical, cosmetic and investigational dermatology · 2025Review
- Recurrence and influencing factors of moderate-to-severe atopic dermatitis after dupilumab withdrawal: a retrospective cohort analysis.Frontiers in medicine · 2025Article
- Dupilumab relieves pruritus both in uremic pruritus and in atopic dermatitis with chronic kidney disease: a retrospective real-world study.Frontiers in medicine · 2025Article
- Real-World Assessment of Dupilumab in Chinese Atopic Dermatitis Patients: Efficacy, Safety, and Impact of Comorbidities.Journal of asthma and allergy · 2025Article
- Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective.Dermatology reports · 2024Article
- Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review.The journal of allergy and clinical immunology. Global · 2024Article
- Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study.Children (Basel, Switzerland) · 2024Article
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up.Journal of asthma and allergy · 2024Article
- Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China.Frontiers in immunology · 2024Observational
- A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children.Drug design, development and therapy · 2024Review
- The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis.Frontiers in medicine · 2023Review
- Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis.Dermatology research and practice · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 20 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundModerate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD.
objectivesA multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from ≥12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined.
methodsData of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes.
resultsOne hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event.
conclusionsDupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.